GERN 📈 Geron - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3741631036
GERN: Cancer, Treatment, Medicine, Therapy, Inhibitor, Drug
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. Web URL: https://www.geron.com
Additional Sources for GERN Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
GERN Stock Overview
| Market Cap in USD | 2,491m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 1996-06-30 |
GERN Stock Ratings
| Growth 5y | 69.8% |
| Fundamental | -49.2% |
| Dividend | - |
| Rel. Strength Industry | 1405 |
| Analysts | 4.5/5 |
| Fair Price Momentum | 3.29 USD |
| Fair Price DCF | - |
GERN Dividends
No Dividends PaidGERN Growth Ratios
| Growth Correlation 3m | -79.3% |
| Growth Correlation 12m | 63.2% |
| Growth Correlation 5y | 75.3% |
| CAGR 5y | 19.84% |
| CAGR/Mean DD 5y | 0.80 |
| Sharpe Ratio 12m | 0.76 |
| Alpha | 35.95 |
| Beta | 0.55 |
| Volatility | 67.21% |
| Current Volume | 5595.7k |
| Average Volume 20d | 8047.7k |
What is the price of GERN stocks?
As of December 26, 2024, the stock is trading at USD 3.34 with a total of 5,595,677 shares traded.
Over the past week, the price has changed by -11.41%, over one month by -18.54%, over three months by -25.94% and over the past year by +44.59%.
As of December 26, 2024, the stock is trading at USD 3.34 with a total of 5,595,677 shares traded.
Over the past week, the price has changed by -11.41%, over one month by -18.54%, over three months by -25.94% and over the past year by +44.59%.
Is Geron a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Geron (NASDAQ:GERN) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -49.15 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GERN as of December 2024 is 3.29. This means that GERN is currently overvalued and has a potential downside of -1.5%.
Probably not. Based on ValueRay Fundamental Analyses, Geron (NASDAQ:GERN) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -49.15 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GERN as of December 2024 is 3.29. This means that GERN is currently overvalued and has a potential downside of -1.5%.
Is GERN a buy, sell or hold?
Geron has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy GERN.
Geron has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy GERN.
- Strong Buy: 5
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for GERN stock price target?
According to ValueRays Forecast Model, GERN Geron will be worth about 3.6 in December 2025. The stock is currently trading at 3.34. This means that the stock has a potential upside of +8.08%.
According to ValueRays Forecast Model, GERN Geron will be worth about 3.6 in December 2025. The stock is currently trading at 3.34. This means that the stock has a potential upside of +8.08%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 7.5 | 123.1% |
| Analysts Target Price | 4.8 | 44.6% |
| ValueRay Target Price | 3.6 | 8.1% |